STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Maze Therapeutics (MAZE) SVP exercises options and sells 5,000 shares

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and a stock sale. On January 22, 2026, she exercised stock options to acquire 2,497 and 2,503 shares of common stock at an exercise price of $10.42 per share. On the same date, she sold 5,000 shares of common stock at a weighted average price of $45.5224 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly held 12,965 shares of Maze Therapeutics common stock and retained stock options covering 486 and 7,869 shares, subject to monthly vesting schedules.

Positive

  • None.

Negative

  • None.
Insider Bachrodt Amy
Role SVP, Finance
Sold 5,000 shs ($228K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 2,497 $0.00 --
Exercise Stock Option (Right to Buy) 2,503 $0.00 --
Exercise Common Stock 2,497 $10.42 $26K
Exercise Common Stock 2,503 $10.42 $26K
Sale Common Stock 5,000 $45.5224 $228K
Holdings After Transaction: Stock Option (Right to Buy) — 486 shares (Direct); Common Stock — 15,462 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.93 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2021, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on March 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bachrodt Amy
(Last) (First) (Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Finance
3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/22/2026 M(1) 2,497 A $10.42 15,462 D
Common Stock 01/22/2026 M(1) 2,503 A $10.42 17,965 D
Common Stock 01/22/2026 S(1) 5,000 D $45.5224(2) 12,965 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $10.42 01/22/2026 M(1) 2,497 (3) 03/03/2031 Common Stock 2,497 $0 486 D
Stock Option (Right to Buy) $10.42 01/22/2026 M(1) 2,503 (4) 02/17/2032 Common Stock 2,503 $0 7,869 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.93 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2021, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
4. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on March 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
/s/ Courtney Phillips, as attorney-in-fact 01/26/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did MAZE SVP of Finance Amy Bachrodt report?

Amy Bachrodt reported exercising stock options to acquire 5,000 Maze Therapeutics common shares at $10.42 per share and selling 5,000 shares at a weighted average price of $45.5224 per share.

How many Maze Therapeutics (MAZE) shares does the SVP of Finance own after these transactions?

After the reported transactions, Amy Bachrodt directly owned 12,965 shares of Maze Therapeutics common stock.

Were the MAZE insider stock sales made under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected under a Rule 10b5-1 trading plan adopted by Amy Bachrodt on September 29, 2025.

What prices were involved in the Maze Therapeutics (MAZE) insider transactions?

The options were exercised at $10.42 per share, and the 5,000 shares of common stock were sold at a weighted average price of $45.5224 per share, with individual sale prices ranging from $45.00 to $45.93.

What stock options does the MAZE SVP of Finance still hold after the Form 4 transactions?

Following the transactions, Amy Bachrodt held stock options covering 486 shares from one grant and 7,869 shares from another, each vesting in 1/48th monthly installments, subject to continued service.

What role does Amy Bachrodt hold at Maze Therapeutics (MAZE)?

Amy Bachrodt is an officer of Maze Therapeutics, serving as SVP, Finance, according to the Form 4.